Currently browsing: News

Fibrodysplasia Ossificans Progressiva

Fibrodysplasia Ossificans Progressiva Pipeline Report, 2024 Updates : In-Depth Analysis Into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects and Companies

The Fibrodysplasia Ossificans Progressiva Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the […]

Read more
Fibrodysplasia Ossificans Progressiva

Actionable Disease Insights from Bedside-to-Bench Investigation in Fibrodysplasia Ossificans Progressiva

Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder of extraskeletal endochondral bone formation. Heterozygous missense gain-of-function mutations in the activin receptor A type I (ACVR1) gene are present in all individuals with sporadic or familial FOP. ACVR1R206H mutations confer increased sensitivity of this bone morphogenetic protein (BMP) family receptor to activation by BMP ligands and […]

Read more
Heterotopic Ossification

Cellular and Molecular Mechanisms of Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva

1. Introduction Fibrodysplasia ossificans progressiva (FOP) is a rare but devastating autosomal dominant genetic disorder characterized by spontaneous or trauma-induced progressive extra-skeletal bone formation, called heterotopic ossification (HO), in skeletal muscles, tendons, and ligaments [1]. HO forms through endochondral ossification, the process that creates most bones during embryonic development [2]. Endochondral ossification occurs through the […]

Read more
Disease

Fibrodysplasia Ossificans Progressiva: A Rare Disease Due to Unawareness, Case Report and Literature Review

Abstract Introduction and importance Fibrodysplasia Ossificans Progressiva is an ultra-rare genetic disorder of progressive soft tissue ossification. Due to unawareness and poor clinical suspicion, the rate of misdiagnosis, delay in diagnosis, and unnecessary diagnostic procedures leading to permanent injury and lifelong disability is common. Here we report this rare genetic disorder in a six years […]

Read more
Fibrodysplasia ossificans progressiva

Fibrodysplasia ossificans progressiva: Two case reports

Introduction Fibrodysplasia ossificans progressiva (FOP) is a rare, progressively debilitating disorder first described in 1692 by Guy Patin [1]. This disease is characterized by progressive heterotopic ossification that forms normal bone in characteristic extraskeletal sites and congenital malformations of the great toes. Progressive episodes of heterotopic ossification occur in characteristic pattern first at the dorsal, axial, […]

Read more
FDA

FDA Approves First Treatment for Fibrodysplasia Ossificans Progressiva

Action The U.S. Food and Drug Administration (FDA) has approved Sohonos (palovarotene) capsules for reduction in the volume of new heterotopic ossification (extra-skeletal bone formation) in adults and children aged 8 years and older for females, and 10 years and older for males with fibrodysplasia ossificans progressiva. Sohonos is the first drug approved for patients with fibrodysplasia […]

Read more
Abnormal Bone

Drug Trial Shows Reduced Abnormal Bone Formation in Those with Fibrodysplasia Ossificans Progressiva

A multisite, international phase 2 trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation in patients with fibrodysplasia ossificans progressiva (FOP). Kathryn Dahir, MD, professor of Medicine in the Division of Endocrinology and Diabetes, served as the principal investigator at Vanderbilt University […]

Read more